Robert Witkow 3/26/24 Robert Witkow 3/26/24

Emet Surgical Opens Crowdsourced Investment Round via StartEngine

Emet Surgical Opens Crowdsourced Investment Round via StartEngine

DENVER and TEL AVIV – March 26, 2024 – Emet Surgical, developers of innovative tools to improve surgery outcomes, today announced that it has opened its StartEngine share offering that will help the company reach its goal of enhancing cancer patient surgery outcomes while providing improved ROI for healthcare providers and insurers.

The company intends to use the net proceeds from its StartEngine offering to purchase components and contract manufacturing services needed for product production, fund research and development efforts, and cover the costs associated with patent applications and FDA approval, among others, all in accordance with the company’s general business plans and goals. Participants in the StartEngine campaign will be among the first investors of a pioneering medical technology company that is part of an estimated $536.12 billion global medical device market.

StartEngine is the leading equity crowdfunding platform. The company has hosted over 1,000 successful funding rounds between Reg. CF and Reg. A

Emet Surgical’s progress to this point has been aided by its membership in the Colorado BioScience Association (CBSA), and participation in Startup Nation Central finder business platform, Israeli NGO promoting Israeli innovation around the world. Both organizations have provided guidance and enabled connections that set Emet Surgical apart from its competitors and other early-stage startups.

Emet Surgical has emerged as a leader in developing cutting-edge surgical solutions that empower healthcare professionals and enhance the quality of patient care. In consultation with medical professionals in the US and Israel, the company has developed solutions that serve as the foundation for more efficient and effective surgeon and pathologist communication.

TrueMargin™ is an easy-to-use tumor margin-marking system that requires no new tools and no new training for surgeons and can be simply added to the surgical and pathology workflows. TrueMargin overcomes conventional tumor marking that is often incomplete by providing specific in-vivo and ex-vivo location and orientation details. Emet Surgical’s goal for TrueMargin is to secure FDA 510(k) clearance as well as other country registrations with volume production and distribution starting 60 days after clearance.

TrueGastro™ is highly visible method of marking the colon for surveillance and surgery. TrueGastro is intended to replace outdated and risky marking techniques made ineffective with the shift from open to minimally invasive colon cancer surgeries. TrueGastro is now in the final engineering phase and testing is anticipated to begin later this year.

“Tumor and structure marking tools currently available do not meet today’s needs nor are keeping pace with advanced surgical techniques,” said Witkow. “Emet Surgical is aiming to improve cancer surgery outcomes by offering innovative tools that enable collaboration between surgeons and other medical specialists who are involved in the patients care. But we can't do it alone. We believe StartEngine will engage investors who appreciate our product goals and investment opportunity. By participating in our StartEngine offering, investors will have an opportunity to get in on the ground floor of a revolutionary offering aiming to improve cancer patient outcomes while empowering surgeons to achieve better outcomes and reduce treatment costs.”

Emet Surgical’s assets consist of intellectual property applications and grants, product designs and the engineering and manufacturing drawings and work plans needed to manufacture products. Its quality and regulatory consultant developed a custom quality management system necessary to support the requirements of US and European Union medical device regulatory bodies. Six thousand product samples have been produced proving the plans and testing of the company’s TrueMargin™ products at independent labs along with their documentation have been submitted to the US FDA in the form of an application for 510(k) clearance. The company has filed applications for two provisional utility patents and two design patents.

Those interested in reserving a spot in the StartEngine funding round can visit https://www.startengine.com/offering/emetsurgical

About Emet Surgical

Taking its name from the Hebrew word for “truth,” Emet Surgical is enabling true surgeon/pathologist collaboration. Emet Surgical’s TrueMargin™ tumor margin marking tools, now under regulatory review, provide surgeons and pathologists with specific in-vivo and ex-vivo tumor margin, location, and orientation details. TrueMargin tools for open, minimally invasive, and robotic procedures enable communication and collaboration not seen before. Founded in 2022, the company is headquartered in Denver with significant operations in Tel Aviv and Haifa, Israel. Additional information is available at www.EmetSurgical.com or by emailing Info@EmetSurgical.com.

# # #

MEDIA CONTACT:

Mark Smith, JPR Communications

marks@jprcom.com

Robert Witkow 3/25/24 Robert Witkow 3/25/24

Emet Surgical Demonstrates Foundation for Efficient, Effective Surgeon and Pathologist Communication at USCAP Annual Meeting

DENVER and TEL AVIV – March 25, 2024 – Emet Surgical, developers of innovative tools to improve surgery outcomes, is exhibiting its tumor marking and mapping tools in Booth No. 453 at the 113th USCAP annual meeting in Baltimore March 23-28.

TrueGastro is a highly visible method of marking the colon for surveillance and surgery. TrueGastro is intended to replace marking techniques made ineffective with the shift from open to minimally invasive colon cancer surgeries.

Post approval studies now planned will measure the effectiveness in improving specific communication between both the surgical and pathology teams. We believe the studies will prove the products achieve better outcomes and reduce treatment costs.

“Our mission is clear: to develop tools for doctors that improve their ability to treat patients, rewriting the narrative of cancer survival,” said Bob Witkow, founder and CEO of Emet Surgical. “Too often poor tumor margin marking negatively impacts communication between the surgeon and pathologist which can result in high re-operation rates. We look forward to showcasing how TrueMargin may minimize these types of situations from occurring. Our goal is to deliver products that save patients from additional surgeries and help healthcare systems achieve measurable productivity improvements and cost savings to attendees of the USCAP event.”

Emet Surgical has filed multiple patent applications for tools, how they are produced and how they are packaged. The company’s goal is to secure FDA 510(k) clearance as well as other country registrations with volume production and distribution starting 60 days after clearance. TrueMagin is currently limited by Federal (or United States) law to investigational use.[ms1]

USCAP’s annual meeting is the largest gathering of pathologists in the world. Attendees can catch up on groundbreaking research, learn first-hand from pathology legends, network with their peers, see what’s new in the exhibit hall, and delve deep into a specialty or gain a broader knowledge base. Additional information and registration is available at https://2024am.uscap.org/

Those interested in meeting with Emet Surgical at the conference or wanting to know more about the TrueMargin and TrueGastro products can sign up on the company’s website at https://www.emetsurgical.com

About Emet Surgical

Taking its name from the Hebrew word for “truth,” Emet Surgical is enabling true surgeon/pathologist collaboration. Emet Surgical’s TrueMargin™ tumor margin marking tools, now under regulatory review, are intended to provide surgeons and pathologists with specific in-vivo and ex-vivo tumor margin, location, and orientation details. TrueMargin tools for open, minimally invasive, and robotic procedures enable communication and collaboration not seen before. Founded in 2022, the company is headquartered in Denver with significant operations in in Tel Aviv and Haifa, Israel. Additional information is available at www.EmetSurgical.com or by emailing Info@EmetSurgical.com.

# # #

MEDIA CONTACT:

Mark Smith, JPR Communications

818-398-1424

Robert Witkow 4/18/23 Robert Witkow 4/18/23

Emet Surgical Aspires to Improve Surgery Outcomes by Enabling True Collaboration Between Cancer Surgeons and Pathologists

It all begins with an idea.

DENVER & TEL AVIV--(BUSINESS WIRE)--Emet Surgical, developers of innovative tools to improve surgery outcomes, launched today with the goal of providing better ways for cancer surgeons and pathologists to collaborate.

“I know from personal experience that getting a cancer diagnosis is an incredibly traumatic experience but is compounded even more so when the patient learns their first surgery was incomplete and a re-surgery is required”

Medical literature points to poor communication between the surgeon and the pathologist as a significant problem, leading to incomplete tumor excisions, and resulting in the need for a second or “re-surgery.” To minimize the need for repeat surgeries, it is important for the surgeon and the pathologist to communicate effectively throughout the process. Traditional tumor margin marking tools, marking only the tumor, puts constraints on their ability to effectively communicate orientation and location details with one another.

In consultation with medical professionals in the US and Israel, the company has developed solutions that serve as the foundation for more efficient and effective surgeon and pathologist communication. TrueMargin™, an investigational product, currently awaiting U.S. FDA 510(k) clearance, is an easy-to-use tumor margin-marking system that requires no new tools and no new training for surgeons and can be simply added to the surgical and pathology workflows.

TrueMargin overcomes conventional tumor marking that is often incomplete by providing specific in-vivo and ex-vivo location and orientation details. The result aligns both the surgical and pathology teams and enables effective and specific communication. Healthcare systems will achieve measurable productivity improvements and cost savings with the use of TrueMargin.

“I know from personal experience that getting a cancer diagnosis is an incredibly traumatic experience but is compounded even more so when the patient learns their first surgery was incomplete and a re-surgery is required,” said Bob Witkow, founder and CEO of Emet Surgical. “What I found true in medical literature going back over 75-years, is that ineffective communication between the surgeon and pathologist oftentimes contributes to incomplete cancer excisions, requiring a re-surgery. I was determined to find a solution that would minimize these types of situations from occurring for others and hopefully make an already traumatizing situation less so.”

Emet Surgical has filed multiple patent applications for tools, how they are produced, and how they are packaged. The company’s goal is to secure FDA 510(k) clearance as well as other country registrations during the third quarter of this year, at which point, it will begin shipping TrueMargin in volume. In addition to its first investigational product, Emet Surgical has additional products ready for introduction by the end of the year pending regulatory approval.

Executive leadership from Emet Surgical will be attending The American Society of Breast Surgeons Annual Meeting in Boston April 26-30. Those interested in meeting with Emet Surgical at the conference or wanting to know more about TrueMargin products when they receive approval can sign up on the company’s website at https://www.emetsurgical.com.

About Emet Surgical

Contacts

MEDIA CONTACT:
Mark Smith, JPR Communications
818-398-1424